|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 35/768 | |
| A61K 35/76 | |||
| C07K 16/30 | |||
| A61K 39/395 | |||
| A61P 35/00 | |||
| A61K 39/12 |
| (11) | Number of the document | 2661278 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12732263.4 |
| Date of filing the European patent application | 2012-01-04 | |
| (97) | Date of publication of the European application | 2013-11-13 |
| (45) | Date of publication and mention of the grant of the patent | 2019-06-19 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2012/020173 |
| Date | 2012-01-04 |
| (87) | Number | WO 2012/094386 |
| Date | 2012-07-12 |
| (30) | Number | Date | Country code |
| 201161429622 P | 2011-01-04 | US |
| (72) |
KIRN, David, US
BELL, John, CA
BREITBACH, Caroline, US
MOON, Anne, US
HWANG, Tae-Ho, KR
LEE, Yu Kyoung, KR
KIM, Mi-kyung, KR
|
| (73) |
SillaJen Biotherapeutics, Inc.,
450 Sansome Street, Suite 650, San Francisco, CA 94111,
US
Sillajen, Inc., 307 Hyowon IC Building Pusan National University San 30, Busan 609-735, KR |
| (54) | TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY (CDC) ANTIBODIES GENERATED BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS, FOR USE IN THE TREATMENT OF CANCER |
| TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY (CDC) ANTIBODIES GENERATED BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS, FOR USE IN THE TREATMENT OF CANCER |